Novo Nordisk updates board employee representative

Novo Nordisk A/S reports a change in its employee representation on the Board of Directors.

Accepted by SEC EDGAR 02/02/2026 - 06:05 AM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Novo Nordisk A/S reports a change in its employee representation on the Board of Directors. Long-time employee representative Thomas Rantzau, who has served on the board since 2018 and worked at the company for 22 years, is leaving to pursue opportunities outside the company.

His alternate, Tanja Villumsen, joins the Board of Directors as an employee representative with effect from 31 January 2026. Novo Nordisk highlights its global scale, employing about 78,500 people in 80 countries and marketing products in around 170 countries.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What board change did Novo Nordisk (NVO) announce in this 6-K?

Novo Nordisk announced that employee representative Thomas Rantzau is stepping down from the Board of Directors, and his alternate, Tanja Villumsen, will join the board as an employee representative with effect from 31 January 2026, maintaining employee representation continuity.

Who is leaving Novo Nordisk’s Board of Directors and why?

Employee representative Thomas Rantzau is leaving Novo Nordisk’s Board of Directors. He has decided to pursue new opportunities outside the company after 22 years of employment and board service since 2018, prompting a change in the employee representative position on the board.

Who is replacing Thomas Rantzau on the Novo Nordisk (NVO) board?

His alternate, Tanja Villumsen, is replacing Thomas Rantzau as an employee representative on Novo Nordisk’s Board of Directors. She joins the board with effect from 31 January 2026, ensuring that employee representation continues without interruption following his departure.

When does the new employee representative join the Novo Nordisk board?

The new employee representative, Tanja Villumsen, joins Novo Nordisk’s Board of Directors with effect from 31 January 2026. This date marks the transition from outgoing representative Thomas Rantzau to his alternate, as disclosed in the company’s report of foreign private issuer.

How large is Novo Nordisk’s global workforce and footprint?

Novo Nordisk employs about 78,500 people in 80 countries and markets its products in around 170 countries. This highlights the company’s broad global footprint as a leading healthcare business focused on serious chronic diseases such as diabetes and related conditions.

Where are Novo Nordisk (NVO) shares and ADRs listed?

Novo Nordisk’s B shares are listed on Nasdaq Copenhagen under the name Novo-B, and its American Depositary Receipts (ADRs) are listed on the New York Stock Exchange under the symbol NVO, giving investors access in both European and U.S. equity markets.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

________________

FORM 6-K

________________

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

January 31, 2026

________________

NOVO NORDISK A/S

 (Exact name of Registrant as specified in its charter)

Novo Allé 1

DK- 2880, Bagsvaerd

Denmark

(Address of principal executive offices)

________________

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F ☒           Form 40-F ☐

 

 

New employee representative on the Board of Directors of Novo Nordisk A/S

Bagsværd, Denmark, 31 January 2026 – Thomas Rantzau, employee representative on the Board of Directors since 2018, has decided to pursue new opportunities outside Novo Nordisk A/S after 22 years of employment. Therefore, he steps down from the Board of Directors and his alternate, Tanja Villumsen, joins the Board of Directors of Novo Nordisk A/S as employee representative with effect from today.

Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 78,500 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.

Contacts for further information:

Media:
Ambre James-Brown	Liz Skrbkova (US)
+45 3079 9289	+1 609 917 0632
globalmedia@novonordisk.com	lzsk@novonordisk.com
Investors:
Michael Novod	Jacob Martin Wiborg Rode
+45 3075 6050	+45 3075 5956
nvno@novonordisk.com	jrde@novonordisk.com
Max Ung	Sina Meyer
+45 3077 6414	+45 3079 6656
mxun@novonordisk.com	azey@novonordisk.com

Alex Bruce	Christoffer Sho Togo Tullin
+45 34 44 26 13	+45 3079 1471
axeu@novonordisk.com	cftu@novonordisk.com
Frederik Taylor Pitter
+1 609 613 0568
fptr@novonordisk.com

Novo Nordisk A/S Investor Relations	Novo Alle 1 2880 Bagsværd Denmark	Telephone: +45 4444 8888	www.novonordisk.com CVR no: 24 25 67 90
			Company announcement No 1 / 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

Date: February 2, 2026   NOVO NORDISK A/S   Maziar Mike Doustdar Chief Executive Officer